Agenus Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
Case Allegations: Agenus is a biotechnology company that focuses on developing immuno-oncology treatments. The class action lawsuit against Agenus claims that the company is working on two main products: balstilimab, an anti-PD-1 treatment that has completed a Phase 2 trial for second-line cervical cancer; and botensilimab (AGEN1181), a CTLA-4 blocking antibody currently in Phase 2 trials for pancreatic cancer and melanoma.
The lawsuit alleges that during the Class Period, Agenus made false or misleading statements and failed to disclose that: (i) the combination of botensilimab and balstilimab was less effective than claimed; and (ii) the clinical results and the potential for regulatory and commercial success of these treatments were overstated.
Additionally, the lawsuit states that on July 18, 2024, Agenus revealed the outcome of a meeting with the U.S. Food and Drug Administration (FDA) about advancing their immunotherapy combination (botensilimab and balstilimab) for treating a specific type of colorectal cancer. The FDA advised against using these results to seek Accelerated Approval, stating that the observed response rates might not lead to improved survival. Following this announcement, Agenus’ stock price dropped nearly 59%, as stated in the complaint.
